期刊文献+

帕金森病患者基底节区质子磁共振波谱研究 被引量:3

Proton magnetic resonance spectroscopy of putamen and substantia nigra in patients with Parkinson disease
下载PDF
导出
摘要 目的利用氢质子磁共振波谱(1H MRS)技术研究帕金森病(PD)患者基底节区(壳核、黑质)的代谢变化及意义。方法PD患者58例和正常对照40例行1H MRS检查,测定双侧壳核的N-乙酰天冬氨酸/肌酸(NAA/Cr)、N-乙酰天冬氨酸/胆碱复合物(NAA/Cho)和胆碱复合物/肌酸(Cho/Cr)比值。结果PD患者症状严重侧肢体的对侧壳核NAA/Cr比值与同侧及对照组相比均明显降低(P<0.05),症状严重侧肢体的对侧壳核NAA/Cr比值为1.406±0.159,同侧为1.502±0.446,对照组为1.539±0.243。而PD患者症状严重侧肢体的对侧壳核Cho/Cr比值、NAA/Cho比值与同侧及对照组相比,差异无统计学意义(P>0.05);PD患者症状严重侧肢体的对侧黑质的NAA/Cr、Cho/Cr和NAA/Cho比值与同侧及对照组相比差异均无统计学意义(P>0.05)。结论1H MRS可以检测到PD患者壳核的NAA/Cr比值降低,这有助于PD的诊断;目前的1H MRS技术尚不能精准地反应PD患者黑质的代谢变化。 Objective To evaluate the utility of the hydrogen proton magnetic resonance spectroscopy (^1H MRS) in the metabolism of the putamen and substantia nigra in patients with Parkinson disease. Methods ^1H MRS was administered to 58 patients with Parkinson disease, and 40 volunteers, N-acetylaspartic acid/creatine(NAA/Cr), N-acetylaspartic acid/choline(NAA/Cho) ,and choline/creatine(Cho/Cr) in bilateral putamen and substantia nigra were determined. Results There was a significant reduction in NAA/Cr ratio in contralateral putamen to the worst clinically affected limbs of the patients with Parkinson disease compared with ipsilateral putamen and controls (P〈0.05). NAA/ Cr ratio in contralateral putamen was 1. 406 ± 0. 159, NAA/Cr ratios in ipsilateral putamen 1. 502±0.446, and NAA/Cr ratios in controls 1. 539 ± 0. 243. There were no significant difference in NAA/Cr, Cho/Cr, NAA/Cho ratio in substantia nigra between the patients with Parkinson disease and controls ( P 〉 0.05). Conclusion ^1H MRS can detect the reduction of the NAA/Cr ratio in Parkinson disease, which helps to Parkinson disease diagnosis. ^1H MRS can not show the metabolic changes precisely in the substantia nigra in patients with Parkinson disease.
出处 《临床荟萃》 CAS 2009年第12期1056-1059,共4页 Clinical Focus
关键词 帕金森病 磁共振波谱学 基底神经节 壳核 黑质 Parkinson disease magnetic resonance spectroscopy basal ganglia putamen, substantia nigra
  • 相关文献

参考文献11

  • 1Gujar SK, Maheshwari S, Bjorkman-Burtscher I, et al. Magnetic resonance spectroscopy [J]. J Neuroophthalmol, 2005,25(3):217-226.
  • 2Rango M, Arighi A, Biondetti P, et al. Magnetic resonance spectroscopy in Parkinson's disease and parkinsonian syndromes[J]. Funct Neurol,2007,22(2) :75-79.
  • 3Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders[J]. Mov Disord, 2003,18 (5):467-486.
  • 4Morrish P. The meaning of negative DAT SPECT and F-Dopa PET scans in patients with clinical Parkinson's disease[J]. Mov Disord,2005,20(1) : 117.
  • 5Antonini A,Benti R,de NotaRis R,et al. 123 I-Ioflupane/Spect binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supanuclear palsy[J]. Neurol Sei, 2003,24 (3) : 149- 150.
  • 6Cropley VL, Fujita M, Bara-Jimenez W, et al. Pre- and postsynaptie dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [ 18F] FDOPA[J]. Psychiatry Res, 2008, 163(2) : 171-182.
  • 7Podell M, Hadjiconstantinou M, Smith MA, et al. Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism[J]. Exp Neurol,2003,179(2) : 159-166.
  • 8Bertolino A,Frye M,Callicott JH,et al. Neuronal pathology in the hippocampal area of patients with bipolar disorder: a study with proton magnetic resonance spectroscopic imaging[J]. Biol Psychiatry,2003,53(10) : 906-913.
  • 9Camieioli RM, Hanstoek CC, Bouehard TP, et al. Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson's disease [J]. Mov Disord, 2007,22 (3) : 382-386.
  • 10Geng Dy, Li YX, Zee CS. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease[J]. Neurosurgery, 2006,58 (2) :256-262.

同被引文献45

  • 1王伟,毛伯镛,张跃康,李鹏.帕金森病丘脑和纹状体质子磁共振波谱研究[J].中国神经精神疾病杂志,2005,31(1):47-49. 被引量:8
  • 2Holshouser B A, Komu M, Moiler H E, et al. Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a multicenter pilot study [J]. Magn Reson Med, 199533(5) :589-594.
  • 3Clarke C E, Lowry M. Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy [J]. Eur J Neurol, 2000,7(6) :661-665.
  • 4O'Neill J, Schuff N, Marks W J Jr, et al. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson' s disease [J]. Mov Disord, 2002,17(5) : 917-927.
  • 5Choe B Y, Park J W, Lee K S, et al. Neuronal laterality in Parkinson' s disease with unilateral symptom by in vivo ^1H magnetic resonance spectroscopy [J]. Invest Radiol, 1998,33 (8):450- 455.
  • 6Hoang T Q, Bluml S, Dubowitz D J, et al. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases [J]. Neurology, 1998,50 (4):1033- 1040.
  • 7Tedesehi G, Litvan I, Bonavita S, et al. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration [J]. Brain, 1997,120( Pt 9) : 1541-1552.
  • 8Bowen B C, Block R E, Sanchez- Ramos J, et al. Proton MR spectroscopy of the brain in 14 patients with Parkinson disease [J]. Am J Neuroradiol, 1995,16( 1 ) :61-68.
  • 9Davie CA, Wenning G K, Barker G J, et al. Differentiation of multiple system atrophy from idiopathic Parkinson' s disease using proton magnetic resonance spectroscopy [J]. Ann Neurol, 1995,37 (2) :204-210.
  • 10Kickler N, Krack P, Fraix V, et al. Glutamate measurement in Parkinson's disease using MRS at 3 T field strength [J]. NMR Biomed, 2007,20(8):757- 762.

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部